EVOK — Evoke Pharma, Inc.

Evoke Pharma, Inc. Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2024 Revenue: $3.3 million, a 97% increase year-over-year from $1.7 million in Q4 2023.
• Full Year 2024 Revenue: Approximately $10.2 million, up from $5.2 million in 2023.
• Net Loss: Q4 2024 net loss of $1.2 million ($0.49 per share), improved from a loss of $2 million ($7.13 per share) in Q4 2023. Full year net loss was approximately $5.4 million ($2.81 per share), down from $7.8 million ($27.97 per share) in 2023.
• Operating Expenses: Q4 operating expenses were approximately $4.5 million, up from $3.6 million in Q4 2023. Full year operating expenses totaled approximately $15.5 million, compared to $12.6 million in 2023.
• Cash Position: As of December 31, 2024, cash and cash equivalents were approximately $13.6 million, expected to fund operations into Q1 2026.

2. Strategic Updates and Business Highlights

• Gimoti Growth: Significant revenue growth driven by increased prescription fulfillment and an expanded prescriber base, with a 46% increase in prescribers year-over-year, totaling 2,553.
• Partnership with Aspen Pharmacy: Transition to Aspen has improved delivery times and insurance authorization processes, contributing to a 72% year-over-year increase in fill rates.
• Market Position: Gimoti is positioned as the only FDA-approved nasal treatment for gastroparesis, with ongoing efforts to challenge the standard of care, oral metoclopramide.
• Clinical Validation: Data presented at conferences supports Gimoti's efficacy over oral alternatives, reinforcing its value proposition in the market.

3. Forward Guidance and Outlook

• 2025 Revenue Projection: Expected net revenue of approximately $16 million, representing a 60% increase over 2024.
• Strategic Focus: Plans to enhance pharmacy partnerships, improve provider engagement, leverage real-world data for payer discussions, and streamline prescription fulfillment processes.

4. Challenges and Points of Concern

• Competitive Landscape: The potential discontinuation of Domperidone may lead to increased demand for Gimoti, but uncertainty remains regarding the volume of patients transitioning to Gimoti.
• Market Dynamics: The evolving gastroenterology landscape with larger practice organizations may complicate access and distribution strategies.
• Prior Authorization Process: Currently, only 50% of prior authorizations are completed, which could hinder prescribing rates. Efforts are being made to improve this through dedicated resources.

5. Notable Q&A Insights

• Competitive Pressures: Management acknowledged the uncertainty surrounding the impact of Domperidone's discontinuation but expressed confidence that Gimoti would capture patients seeking alternatives.
• Medicaid Strategy: The percentage of Medicaid and Medicare prescriptions has increased from 2% to 5-7% over the year, indicating successful expansion efforts in those markets.
• Provider Engagement: Increased awareness and interest from providers in Gimoti were noted, suggesting a positive trend in market penetration.

Overall, Evoke Pharma demonstrated strong financial growth in 2024, driven by strategic initiatives and a focus on improving patient access to Gimoti, while also navigating challenges in the competitive landscape and operational processes.